A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
Fecha
2023-01-05Autor
Montoya, Juan Manuel
Izu Belloso, Rosa María
Sánchez Díez, Ana
Cancho Galán, Goikoane
Martínez de la Fuente Martínez, Ildefonso Abel
Metadatos
Mostrar el registro completo del ítem
Life 13(1) : (2023) // Article ID 155
Resumen
Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the corresponding patient. Methods: We extracted the 1134 most frequent mutations in melanoma, and we associated each of them to a vector with 10 components estimated with different bioinformatics tools, for which we found an aggregated value according to a set of weights, and then we ordered them in decreasing order of the scores. Results: We prepared a universal table of the most frequent mutations in melanoma ordered in decreasing order of viability to be used as candidate vaccines, so that the selection of a set of appropriate peptides for each particular patient can be easily and quickly implemented according to their specific mutanome and transcription profile. Conclusions: We have shown that the techniques that are commonly used for the design of personalized anti-tumor vaccines against malignant melanoma can be adapted for the design of universal rankings of neoantigens that originate personalized vaccines when the mutanome and transcription profile of specific patients is considered, with the consequent savings in time and money, shortening the design and production time.
Colecciones
Excepto si se señala otra cosa, la licencia del ítem se describe como © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).